Allurion Announces Publication of Randomized, Double-Blind Study Demonstrating Significant Improvement in Obesity-Related Co-Morbidities

Rhea-AI Summary

Allurion Technologies, Inc. (NYSE: ALUR) announced the publication of a study demonstrating significant reductions in type 2 diabetes, hypertension, and obstructive sleep apnea in just 4 months on the Allurion Program. Weight loss was 13.7% at 4 months, with resolution of type 2 diabetes, hypertension, and obstructive sleep apnea observed in 55.5%, 58.8%, and 57.8%, respectively. Results improved with the addition of oral GLP-1 agonist semaglutide, with weight loss improving to 17.6% and co-morbidity resolution improving to 64.7%, 64.3%, and 72%, respectively.

Insights

Medical Research Analyst

The recent study published by Allurion Technologies showcases a significant stride in the treatment of obesity-related comorbidities. The integration of the Allurion Program with oral GLP-1 agonist semaglutide presents a notable advancement in medical protocols for managing type 2 diabetes, hypertension and obstructive sleep apnea. The reported weight loss and comorbidity resolution rates are substantial when compared to the usual outcomes of obesity interventions.

It is important to note that the GLP-1 agonist semaglutide is a medication that mimics the incretin hormone, which is known to decrease glucagon release and appetite, ultimately leading to weight loss. The Allurion Program's synergy with semaglutide could signify a paradigm shift in non-surgical obesity treatment, potentially affecting the market for anti-obesity devices and pharmaceuticals. The study's findings could lead to increased demand for such combined treatments, impacting Allurion's market share and revenue.

Healthcare Industry Analyst

Allurion Technologies' study outcomes could have substantial implications for the healthcare industry, particularly in the obesity treatment market. The data suggests that the Allurion Program, complemented by semaglutide, may offer a more effective solution for patients, which is an important consideration for healthcare providers and insurers. This could lead to a shift in how obesity and its related conditions are managed, potentially influencing insurance coverage policies and healthcare protocols.

Furthermore, the increased efficacy of the Allurion Program with semaglutide may attract a larger patient base, including those who have not had success with other treatments or are seeking non-invasive options. This could result in a competitive advantage for Allurion and impact the stock prices of competitors in the space. The study's publication in a peer-reviewed journal lends credibility and could facilitate the adoption of this combined treatment approach.

Financial Analyst

The publication of this study has potential financial implications for Allurion Technologies and its investors. The positive results could lead to an increase in the company's valuation due to anticipated growth in sales and market expansion. The resolution rates of obesity-related comorbidities could position Allurion as a leader in the market, potentially attracting partnership opportunities and increasing investor confidence.

One must consider the cost-effectiveness of the Allurion Program coupled with semaglutide. If this combined approach proves to be cost-effective, it could result in a higher adoption rate. Conversely, the cost of GLP-1 agonists and the Allurion Program could be a barrier for some patients, which may limit market penetration. It is crucial to monitor Allurion's pricing strategy and reimbursement landscape to evaluate the potential financial impact on the company's performance.

Allurion Program led to resolution of type 2 diabetes, hypertension, and obstructive sleep apnea in just 4 months in over half of the patients treated

Results improved with addition of oral GLP-1 agonist semaglutide

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a randomized, double-blind study in Obesity Surgery that demonstrated significant reductions in type 2 diabetes, hypertension, and obstructive sleep apnea in just 4 months on the Allurion Program. These results improved with the addition of oral GLP-1 agonist semaglutide.

In the study, 115 patients were randomized to either the Allurion Program with or without oral semaglutide and followed for 4 months. In patients randomized to the Allurion Program alone, weight loss was 13.7% at 4 months and resolution of type 2 diabetes, hypertension, and obstructive sleep apnea was observed in 55.5%, 58.8%, and 57.8%, respectively. Weight loss improved to 17.6% in the group treated with the Allurion Program and oral semaglutide and co-morbidity resolution improved to 64.7%, 64.3%, and 72%, respectively.

“We have been extremely pleased with the results we are seeing in medically complex patients with the Allurion Program, especially the speed with which co-morbidities resolve,” said Mohit Bhandari, M.D., President of IRCAD India and senior author on the study. “We have seen that oral GLP-1 agonists alone are often insufficient to generate such significant results but using them as a tool to augment the results of the Allurion Program could be a promising treatment approach in the future.”

Allurion recently published findings indicating that providers are interested in combining the Allurion Program with anti-obesity medications and that the rise of GLP-1 agonists has increased patient enquiries and boosted awareness of weight loss treatments like the Allurion Program.

“We believe the results of this study provide further validation of the rapid impact the Allurion Program can have in patients with obesity and other co-morbidities,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. “By combining the Allurion Program with anti-obesity medications, we may be able to improve outcomes even further and reach an even broader segment of the population."

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Gastric Balloon is an investigational device in the United States.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.

Forward-Looking Statements

This press release may contain certain forward-looking statements within the meaning of the U.S. federal and state securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “target,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions and include statements regarding: Allurion’s expectations for demand of, and growth catalysts for, the Allurion Program; the impact of the use of the Allurion Program alone and in combination with other treatments such as GLP-1 drugs; and tailwinds from the rise of GLP-1 drugs and the macroeconomic environment. Forward-looking statements are predictions, projections and other statements about future events that reflect the current beliefs and assumptions of Allurion’s management based on information currently available to them and, as a result, are subject to risks and uncertainties. Many factors could cause actual future results or developments to differ materially from the forward-looking statements in this press release, including but not limited to (i) the ability of Allurion to obtain regulatory approval for and successfully commercialize the Allurion Program, (ii) the timing of and results from its clinical studies and trials, (iii) the evolution of the markets in which Allurion competes and the rise of GLP-1 drugs, (iv) the ability of Allurion to defend its intellectual property and satisfy regulatory requirements, (v) the impact of the COVID-19 pandemic, Russia-Ukraine war and Israel-Hamas war on Allurion’s business, (vi) Allurion’s expectations regarding its market opportunities and (vii) the risk of economic downturns and a changing regulatory landscape in the highly competitive industry in which Allurion operates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q on November 14, 2023, and other documents filed by Allurion from time to time with the U.S. Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Allurion assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Allurion does not give any assurance that it will achieve its expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240111535032/en/

US Media

Brian Ruby

ICR

(203) 682-8268

brian.ruby@icrinc.com

Global Media

Cedric Damour

PR Manager

+33 7 84 21 02 20

cdamour@allurion.com

Investor Contact

Mike Cavanaugh, Investor Relations

ICR Westwicke

(617) 877-9641

mike.cavanaugh@westwicke.com

Source: Allurion Technologies, Inc.

FAQ

What did Allurion Technologies, Inc. announce?

Allurion Technologies, Inc. announced the publication of a study demonstrating significant reductions in type 2 diabetes, hypertension, and obstructive sleep apnea in just 4 months on the Allurion Program.

What were the results of the study?

The study showed weight loss of 13.7% at 4 months, with resolution of type 2 diabetes, hypertension, and obstructive sleep apnea observed in 55.5%, 58.8%, and 57.8%, respectively. Results improved with the addition of oral GLP-1 agonist semaglutide, with weight loss improving to 17.6% and co-morbidity resolution improving to 64.7%, 64.3%, and 72%, respectively.

Who is the President of IRCAD India and senior author on the study?

Mohit Bhandari, M.D., is the President of IRCAD India and senior author on the study.

Who is the Founder and CEO of Allurion Technologies, Inc.?

Dr. Shantanu Gaur is the Founder and CEO of Allurion Technologies, Inc.

What medication was used in the study to augment the results of the Allurion Program?

The addition of oral GLP-1 agonist semaglutide was used to augment the results of the Allurion Program in the study.